GVAX Uses, Dosage, Side Effects and more
GVAX is a chimeric monoclonal antibody which is used as an immunosuppressive drug.
GVAX is a monoclonal antibody that is being studied in the treatment of follicular non-Hodgkin lymphoma. Monoclonal antibodies are made in the laboratory and can locate and bind to cancer cells. GVAX binds to the protein CD80, which is found on certain normal and cancerous white blood cells.
| Trade Name | GVAX |
| Generic | Galiximab |
| Galiximab Other Names | Anti-CD80 monoclonal antibody, Galiximab |
| Type | |
| Groups | Investigational |
| Therapeutic Class | |
| Manufacturer | |
| Available Country | |
| Last Updated: | January 7, 2025 at 1:49 am |
Uses
Investigated for use/treatment in lymphoma (non-hodgkin's), psoriasis and psoriatic disorders, bone metastases, multiple myeloma, prostate cancer, and rheumatoid arthritis.
How GVAX works
GVAX, an IgG(1) anti-CD80 antibody, binds to CD80, a costimulatory molecule involved in T-cell activation. Reduction in lesional, activated T cells induces improvement in psoriatic plaques.
Half Life
13 to 24 days
